Clinical Trial Detail

NCT ID NCT03017131
Title Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

ovarian carcinoma

fallopian tube carcinoma

peritoneal carcinoma

Therapies

Aldesleukin + Cyclophosphamide + Decitabine + NY-ESO-1-c259T

Age Groups: adult senior

No variant requirements are available.